Published in Drug Week, January 7th, 2005
The study reported a statistically significant difference in event-free survival of 25.2 months versus 13.7 months (P<0.001) after a minimum of 6 months of treatment with melphalan, prednisone, and thalidomide versus melphalan and prednisone (MP) alone.
This phase II study reported clinical data in newly diagnosed multiple myeloma...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.